Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomas, E.
Right arrow Articles by Silman, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, E.
Right arrow Articles by Silman, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 37, 1069-1076, Copyright © 1998 by British Society for Rheumatology

ORIGINAL PAPERS

Sjogren's syndrome: a community-based study of prevalence and impact

E Thomas, EM Hay, A Hajeer and AJ Silman
ARC Epidemiology Research Unit, University of Manchester.

OBJECTIVE: Using the European Community (EC) criteria for classification Vitali et al. Arthritis Rheum 1993;36:340 7, we report the prevalence estimates of Sjogren's syndrome (SS) from a general population and present the first population data to assess the impact of the syndrome. METHODS: A cross-sectional population-based survey performed on 1000 adults, aged 18-75 yr, randomly selected from a population register. Responders to the initial postal phase were invited for an interview. The five criteria measured at interview were: (1) the reporting of subjective oral symptoms lasting for > 3 months; (2) the reporting of subjective ocular symptoms lasting for >3 months; (3) Schirmer-I test; (4) unstimulated salivary flow; (5) autoantibodies [Ro (SS-A), La (SS-B), rheumatoid factor (RF), antinuclear antibodies (ANA)]. SS was diagnosed if at least four of these five criteria were positive. The MOS Short-form 36 (SF-36), General Health Questionnaire (GHQ) and the Health and Fatigue Questionnaire (HFQ) were completed by subjects after the interview, and scores were compared between those with and without a diagnosis of SS. RESULTS: A total of 341 subjects completed both the postal questionnaire and home visit. A diagnosis of SS could be given to 13 subjects. After adjusting for the presence of possible bias due to non-response, our best estimate of the prevalence of SS in the study population was 33 per 1000 subjects (95% CI 22 44). The prevalence of the disorder was higher in females (38; 95% CI 27-52) and for those subjects aged > or = 55 yr (46; 95% CI 34-61). Those subjects diagnosed positively were more impaired for each of the eight dimensions of the SF-36 than those without a diagnosis, and also suffered from higher levels of depression and fatigue. CONCLUSIONS: SS affects approximately 3-4% of adults and in the general population appears to be associated with a clinically significant impairment of a subject's health and well-being.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
A Hida, M Akahoshi, Y Takagi, K Ashizawa, M Imaizumi, M Soda, R Maeda, E Nakashima, H Ida, A Kawakami, et al.
Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors
Ann Rheum Dis, May 1, 2008; 67(5): 689 - 695.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
S H Wong, M Boggild, T P Enevoldson, and N A Fletcher
Myelopathy but normal MRI: where next?
Practical Neurology, April 1, 2008; 8(2): 90 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
C. M. Stewart, K. M. Berg, S. Cha, and W. H. Reeves
Salivary Dysfunction and Quality of Life in Sjogren Syndrome: A Critical Oral-Systemic Connection
J Am Dent Assoc, March 1, 2008; 139(3): 291 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S A Chambers, S C Charman, A Rahman, and D A Isenberg
Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality
Ann Rheum Dis, September 1, 2007; 66(9): 1173 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Ramos-Casals and P. Brito-Zeron
Emerging biological therapies in primary Sjogren's syndrome
Rheumatology, September 1, 2007; 46(9): 1389 - 1396.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
P. POROLA, M. LAINE, L. VIRKKI, P. PODUVAL, and Y. T. KONTTINEN
The Influence of Sex Steroids on Sjogren's Syndrome
Ann. N.Y. Acad. Sci., June 1, 2007; 1108(1): 426 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Callaghan, A. Prabu, R. B. Allan, A. E. Clarke, N. Sutcliffe, Y. St. Pierre, C. Gordon, S. J. Bowman, and the UK Sjogren's Interest Group
Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome
Rheumatology, January 1, 2007; 46(1): 105 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
W. W. Eaton, M. Byrne, H. Ewald, O. Mors, C.-Y. Chen, E. Agerbo, and P. B. Mortensen
Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers
Am J Psychiatry, March 1, 2006; 163(3): 521 - 528.
[Abstract] [Full Text] [PDF]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
D. W Matear, D Locker, M Stephens, and H P Lawrence
Associations between xerostomia and health status indicators in the elderly
The Journal of the Royal Society for the Promotion of Health, March 1, 2006; 126(2): 79 - 85.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
Y. Alamanos, N. Tsifetaki, P. V. Voulgari, A. I. Venetsanopoulou, C. Siozos, and A. A. Drosos
Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003
Rheumatology, February 1, 2006; 45(2): 187 - 191.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. E. Smedby, H. Hjalgrim, J. Askling, E. T. Chang, H. Gregersen, A. Porwit-MacDonald, C. Sundstrom, M. Akerman, M. Melbye, B. Glimelius, et al.
Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
J Natl Cancer Inst, January 4, 2006; 98(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P I Trontzas and A A Andrianakos
Sjogren's syndrome: a population based study of prevalence in Greece. The ESORDIG study
Ann Rheum Dis, August 1, 2005; 64(8): 1240 - 1241.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. J. Dawson, V. L. Caulfield, J. B. Stanbury, A. E. Field, S. E. Christmas, and P. M. Smith
Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase
Rheumatology, April 1, 2005; 44(4): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Sanchez-Guerrero, M. R. Perez-Dosal, F. Cardenas-Velazquez, A. Perez-Reguera, E. Celis-Aguilar, A. E. Soto-Rojas, and C. Avila-Casado
Prevalence of Sjogren's syndrome in ambulatory patients according to the American-European Consensus Group criteria
Rheumatology, February 1, 2005; 44(2): 235 - 240.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Mertzanis, L. Abetz, K. Rajagopalan, D. Espindle, R. Chalmers, C. Snyder, B. Caffery, T. Edrington, T. Simpson, J. D. Nelson, et al.
The Relative Burden of Dry Eye in Patients' Lives: Comparisons to a U.S. Normative Sample
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 46 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
C van Noord, H Hooijkaas, B C M Dufour-van den Goorbergh, P M van Hagen, P L A van Daele, and J P van de Merwe
Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjogren's syndrome
Ann Rheum Dis, January 1, 2005; 64(1): 160 - 162.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. J. Bowman, D. A. Booth, and R. G. Platts
Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool
Rheumatology, June 1, 2004; 43(6): 758 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
S. E. Moss, R. Klein, and B. E. K. Klein
Incidence of Dry Eye in an Older Population
Arch Ophthalmol, March 1, 2004; 122(3): 369 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. Jimenez, S. Aiba-Masago, I. Al Hashimi, N. Vela-Roch, G. Fernandes, C.-K. Yeh, N. Talal, and H. Dang
Activated caspase 3 and cleaved poly(ADP-ribose)polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjogren's syndrome
Rheumatology, March 1, 2002; 41(3): 338 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Klepfish, J. Friedman, Y. Schechter, and A. Schattner
Autoimmune neutropenia, thrombocytopenia and Coombs positivity in a patient with primary Sjogren's syndrome
Rheumatology, August 1, 2001; 40(8): 948 - 949.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
W. Fiebiger, G. Stummvoll, G. Weinlander, and M. Raderer
Does pantoprazole alleviate mouth dryness in patients with Sjogren's syndrome?
Rheumatology, January 1, 2001; 40(1): 110 - 110.
[Full Text] [PDF]

Home page
 QJMHome page
A. Schattner, J. Friedman, A. Klepfish, and A. Berrebi
Immune cytopenias as the presenting finding in primary Sjogren's syndrome
QJM, December 1, 2000; 93(12): 825 - 829.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
C. Gordon and A. E Clarke
Quality of life and economic evaluation in SLE clinical trials
Lupus, October 1, 1999; 8(8): 645 - 654.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.